1. Home
  2. FNWD vs MOLN Comparison

FNWD vs MOLN Comparison

Compare FNWD & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Finward Bancorp

FNWD

Finward Bancorp

HOLD

Current Price

$37.47

Market Cap

154.0M

Sector

Finance

ML Signal

HOLD

Logo Molecular Partners AG

MOLN

Molecular Partners AG

BUY

Current Price

$4.61

Market Cap

158.9M

Sector

N/A

ML Signal

BUY

Company Overview

Basic Information
Metric
FNWD
MOLN
Founded
1994
2004
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Savings Institutions
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
154.0M
158.9M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
FNWD
MOLN
Price
$37.47
$4.61
Analyst Decision
Buy
Buy
Analyst Count
1
2
Target Price
$34.00
$8.38
AVG Volume (30 Days)
18.5K
5.9K
Earning Date
01-27-2026
03-13-2026
Dividend Yield
1.30%
N/A
EPS Growth
N/A
N/A
EPS
1.88
N/A
Revenue
$66,245,999.00
N/A
Revenue This Year
$16.40
N/A
Revenue Next Year
$5.36
$999.99
P/E Ratio
$19.66
N/A
Revenue Growth
N/A
N/A
52 Week Low
$26.16
$3.36
52 Week High
$39.99
$5.10

Technical Indicators

Market Signals
Indicator
FNWD
MOLN
Relative Strength Index (RSI) 52.69 60.72
Support Level $36.97 $4.33
Resistance Level $38.99 $4.74
Average True Range (ATR) 0.84 0.20
MACD 0.01 0.06
Stochastic Oscillator 64.78 86.75

Price Performance

Historical Comparison
FNWD
MOLN

About FNWD Finward Bancorp

Finward Bancorp is a bank holding company, which engages in the provision of financial services. It offers products and services related to Personal Banking, Cash Management, Saving Account, ebanking, Wealth Management, and Insurance Services. It is engaged in the business of attracting deposits from the general public and the origination of loans, mostly upon the security of single-family residences and commercial real estate, construction loans, commercial business loans, and municipal loans. Geographically, the activities are carried out through the United States.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Share on Social Networks: